CSIMarket
 


HOSPIRA, INC.  (HSP)
Other Ticker:  
 
 

HSP's Capital Expenditures Growth by Quarter and Year

Hospira,'s Capital Expenditures results by quarter and year




HSP Capital Expenditures (in millions $) FY 2014 FY 2013 FY 2012 FY 2011
IV Quarter December - -249.90 88.30 79.20
III Quarter September 94.20 95.80 64.40 72.70
II Quarter June 89.70 84.10 70.10 76.40
I Quarter March 95.10 68.60 67.30 62.20
FY   279.00 -1.40 290.10 290.50



HSP Capital Expenditures third quarter 2014 Y/Y Growth Comment
Hospira, Inc. reported decrease in Capital Expenditures in the third quarter by -1.67% to $ 94.20 millions, from the same quarter in 2013.
The decrease in the third quarter Hospira, Inc.'s Capital Expenditures compares unfavorably to the Company's average Capital Expenditures growth of 1.34%.

Looking into third quarter results within Major Pharmaceutical Preparations industry 89 other companies have achieved higher Capital Expenditures growth. While Hospira, Inc.' s Capital Expenditures decline of -1.67% ranks overall at the positon no. 1911 in the third quarter.




HSP Capital Expenditures ( Y/Y Growth %) 2014
2013 2012 2011
IV Quarter December - - 11.49 % -62.01 %
III Quarter September -1.67 % 48.76 % -11.42 % -48.73 %
II Quarter June 6.66 % 19.97 % -8.25 % -3.78 %
I Quarter March 38.63 % 1.93 % 8.2 % 53.2 %
FY   - - -0.14 % -38.23 %

Financial Statements
Hospira,'s third quarter 2014 Capital Expenditures $ 94.20 millions HSP's Income Statement
Hospira,'s third quarter 2013 Capital Expenditures $ 95.80 millions Quarterly HSP's Income Statement
New: More HSP's historic Capital Expenditures Growth >>


HSP Capital Expenditures (Quarter on Quarter Growth %)

2014
2013 2012 2011
IV Quarter December - - 37.11 % 8.94 %
III Quarter September 5.02 % 13.91 % -8.13 % -4.84 %
II Quarter June -5.68 % 22.59 % 4.16 % 22.83 %
I Quarter March - -22.31 % -15.03 % -70.17 %
FY (Year on Year)   - - -0.14 % -38.23 %




Capital Expenditures third quarter 2014 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #90
Healthcare Sector #237
Overall #1911

Capital Expenditures Y/Y Growth Statistics
High Average Low
53.2 % 1.34 % -100 %
(March 31, 2011)   (Dec 31 2011)
Capital Expenditures third quarter 2014 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #90
Healthcare Sector #237
Overall #1911
Capital Expenditures Y/Y Growth Statistics
High Average Low
53.2 % 1.34 % -100 %
(March 31, 2011)   (Dec 31 2011)

Capital Expenditures by Quarter for the Fiscal Years 2011, 2012, 2013, 2014

Hospira,'s Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
130.18 % 12.01 % -100 %
(June 30, 2009)   (Dec 31 2011)


HSP's III. Quarter Q/Q Capital Expenditures Comment
HOSPIRA, INC. achieved in the III. Quarter 2014 below company average Capital Expenditures increase of 5.02% quarter on quarter, to $ 94.20 millions.

Within Major Pharmaceutical Preparations industry 85 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Hospira,'s Capital Expenditures growth quarter on quarter, overall rank is 1902.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #86
Healthcare Sector #252
Overall #1902
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #86
Healthcare Sector #252
Overall #1902
Capital Expenditures Q/Q Growth Statistics
High Average Low
130.18 % 12.01 % -100 %
(June 30, 2009)   (Dec 31 2011)


HSP's III. Quarter Q/Q Capital Expenditures Comment
HOSPIRA, INC. achieved in the III. Quarter 2014 below company average Capital Expenditures increase of 5.02% quarter on quarter, to $ 94.20 millions.

Within Major Pharmaceutical Preparations industry 85 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Hospira,'s Capital Expenditures growth quarter on quarter, overall rank is 1902.


Hospira,'s 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep. 30, 2014)
12 Months Ending
(June 30. 2014)
12 Months Ending
(March 31, 2014)
12 Months Ending
(Dec 31 2013)
12 Months Ending
(Sep. 30, 2013)
Cumulative Capital Expenditures 12 Months Ending $ 384.00 $ 385.60 $ 380.00 $ -1.40 $ 336.80
Y / Y Capital Expenditures Growth (TTM) 14.01 % 26.26 % 30.4 % - -
Year on Year Capital Expenditures Growth Overall Ranking # 1114 # 1238 # 1238 # 1238 # 1144
Seqeuential Capital Expenditures Change (TTM) -0.41 % 1.47 % 7.5 % - 10.28 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1476 # 1784 # 0 # 0 # 1513




Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Sep. 30, 2014 period, Hospira,'s cumulative twelve months Capital Expenditures were $ 384 millions, company would post below average annual Capital Expenditures growth of 10.28% year on year, if the fiscal year would end at Sep. 30, 2014.
A slow-down in the Hospira,'s Capital Expenditures growth from the 89.7% growth in June 30. 2014.

In the Healthcare sector 108 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1114, from total ranking in previous quarter at 1238.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
490.45 %
25.96 %
-30.8 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 43
Healthcare Sector # 109
Overall # 1114

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
538.18 %
35.2 %
-40.83 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 152
S&P 500 # 1476
Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Sep. 30, 2014 period, Hospira,'s cumulative twelve months Capital Expenditures were $ 384 millions, company would post below average annual Capital Expenditures growth of -40.83% year on year, if the fiscal year would end at Sep. 30, 2014.
A slow-down in the Hospira,'s Capital Expenditures growth from the 89.7% growth in June 30. 2014.

In the Healthcare sector 108 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1114, from total ranking in previous quarter at 1238.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
490.45 %
25.96 %
-30.8 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 43
Healthcare Sector # 109
Overall # 1114

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
538.18 %
35.2 %
-40.83 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 152
S&P 500 # 1476




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
HSP's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for HSP's Competitors
Capital Expenditures Growth for Hospira,'s Suppliers
Capital Expenditures Growth for HSP's Customers

You may also want to know
HSP's Annual Growth Rates HSP's Profitability Ratios HSP's Asset Turnover Ratio HSP's Dividend Growth
HSP's Roe HSP's Valuation Ratios HSP's Financial Strength Ratios HSP's Dividend Payout Ratio
HSP's Roa HSP's Inventory Turnover Ratio HSP's Growth Rates HSP's Dividend Comparisons



Companies with similar Capital Expenditures increase for the quarter ending Sep. 30, 2014 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep. 30, 2014
Pfizer Inc-1.08%$ -1.079 millions
HOSPIRA, INC.-1.67%$ -1.670 millions
Boston Scientific Corporation-1.75%$ -1.754 millions
Teleflex Incorporated-2.10%$ -2.102 millions
West Pharmaceutical Services Inc -2.39%$ -2.389 millions
Royalty Pharma Plc-2.60%$ -2.597 millions
Amgen Inc -2.86%$ -2.857 millions
Bruker Corporation-2.94%$ -2.941 millions
Cepheid-3.77%$ -3.765 millions
Zimmer Biomet Holdings, Inc.-4.04%$ -4.037 millions
Volcano Corp-5.60%$ -5.603 millions
Wright Medical Group N v -5.99%$ -5.986 millions
Nxstage Medical, Inc.-6.02%$ -6.021 millions
Five Star Senior Living Inc -6.62%$ -6.620 millions
Teva Pharmaceutical Industries Ltd-7.02%$ -7.018 millions
Johnson and Johnson-7.17%$ -7.169 millions
Prestige Consumer Healthcare Inc -7.43%$ -7.435 millions
Luna Innovations Inc-7.82%$ -7.823 millions
Chemed Corporation-8.83%$ -8.827 millions
Merck and Co Inc -9.86%$ -9.859 millions
Healthcare Services Group Inc -11.13%$ -11.133 millions
Dentsply Sirona Inc -11.54%$ -11.536 millions
Exact Sciences Corporation-13.44%$ -13.435 millions
Genmark Diagnostics Inc -13.65%$ -13.653 millions
Bristol Myers Squibb Co-13.71%$ -13.710 millions
COVIDIEN LTD.-14.16%$ -14.159 millions
Ptc Therapeutics inc -14.24%$ -14.239 millions
Amicus Therapeutics inc -14.29%$ -14.286 millions
Amsurg Corp-14.63%$ -14.626 millions
Parexel International Corp-14.88%$ -14.882 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

LFT's Profile

Stock Price

LFT's Financials

Business Description

Fundamentals

Charts & Quotes

LFT's News

Suppliers

LFT's Competitors

Customers & Markets

Economic Indicators

LFT's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071